Systemic administration of TRL7/8 agonists enhances anti-tumor immunity by enhancing dendritic cell (DC) activation, but also causes systemic toxicity. Here, the authors show that, in tumor mouse models, a radiotherapy-activated, N-oxide imidazoquinoline prodrug promotes controlled, local activation of intratumoral DC-T cell dynamics, while promoting systemic anti-tumor responses.
- Xiaozhe Yin
- Zexuan Ding
- Yang-Xin Fu
